Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04744675

Peripheral Nerve Injections for CRPS

Background Complex regional pain syndrome (CRPS) is characterized by intense pain, loss of function, and associated with motor, trophic, sudomotor, and/or vasomotor changes of the affected extremity. Upper extremity CRPS is seen frequently in electrodiagnostic, neurology, and musculoskeletal clinics and occurs in up to one-third of patients who have undergone common surgical procedures (i.e. carpal tunnel surgery). To date, there is a limited understanding of the underlying pathophysiology of CRPS. As a consequence, few effective treatment options are available.

Peripheral nerve blocks have proven to be successful in reducing pain for several musculoskeletal and neurologic conditions. Similarly, this procedure could be used to block somatic and autonomic sensory fibers which are thought to contribute to CRPS. In a small exploratory study, investigators found peripheral nerve blocks in the upper extremity (suprascapular and median nerves) were well-tolerated in patients with CRPS and resulted in a 56% and 37% pain reduction in the shoulder and hand 2 weeks after injection, respectively. While this is highly encouraging, large randomized placebo-controlled trials (RCTs) are necessary to demonstrate effectiveness and safety of nerve blocks for this population before it is accepted into clinical practice. This proposal is a phase II feasibility study that will test the critical elements necessary for performing such a RCT.

Methods The investigators will recruit participants (≥18 years old) from The Ottawa Hospital, Bruyère Continuing Care (Elisabeth Bruyère Hospital, St-Vincent Hospital), and Providence Care Hospital (Kingston, ON), meeting the well-established clinical Budapest criteria for upper extremity CRPS and having a visual analog scale (VAS) pain score of at least 40 mm (to avoid flooring effect). Participants will be block-randomized by the Ottawa Methods Centre to receive injections of either A) intervention (suprascapular, median, and ulnar nerves) with bupivacaine and triamcinolone acetonide, or B) placebo (saline). All participants will receive standard care for CRPS.

Primary outcomes will focus on crucial methodologic aspects for the future RCT, including: (1) level of recruitment, (2) rate of acceptance from eligible patients to the randomization procedure, (3) blinding efficacy, (4) degree of patient retention, (5) rate of data completion, and (6) rate of adverse events for both the placebo and intervention groups.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Elisabeth Bruyere Hospital, Ottawa, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to provide signed and dated informed consent form
  • Male or female, aged ≥18 years old
  • Satisfy the Budapest Criteria for upper extremity CRPS
  • A VAS score of at least 40 mm in the upper extremity to avoid flooring effect for injection-related pain reduction

Exclusion criteria

  • Uncontrolled hypertension (>180/110)
  • Sepsis
  • Bleeding diathesis
  • Active cancer
  • Brachial plexus injuries
  • Neurological language deficits precluding participation
  • Mini mental state examination score < 23
  • Acute mental illness (An acute mental illness is characterized by clinically significant symptoms of any metal health illness that requires immediate treatment. The physician making the recommendation to be part of the study. If the patient exhibits symptoms of any mental health illness that is not being treated by either the recommending physician or another member of the patient's care team the patient will not be recommended to participate in the study)
  • Patients who are pregnant or breastfeeding

Treatment and study plan

Triamcinolone Acetonide 40mg/mL

Drug

Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.

Other names: Kenalog

Saline injection

Drug

Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.

Bupivacaine

Drug

Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.

Other names: Marcaine

Primary outcomes

  1. Recruitment

    Time frame: Week -2

    Number of participants who are successfully recruit into the study.

  2. Randomization

    Time frame: Week 0

    Number of participants who accept being randomized into either the intervention or placebo treatment arms and receive the injection accordingly.

  3. Blinding - Participant

    Time frame: Week 0

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  4. Blinding - Participant

    Time frame: Week 2

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  5. Blinding - Participant

    Time frame: Week 6

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  6. Blinding - Participant

    Time frame: Week 12

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  7. Blinding - Interventionist

    Time frame: Week 0

    The interventionist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  8. Blinding - Physiotherapist

    Time frame: Week 2

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  9. Blinding - Physiotherapist

    Time frame: Week 6

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  10. Blinding - Physiotherapist

    Time frame: Week 12

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

  11. Retention

    Time frame: Week 12

    The percentage of participants who remained in the study for the entire duration of their planned involvement.

  12. Data completion

    Time frame: Week 12

    The percentage of participants who complete all of the study questionnaires

  13. Rate of Adverse events

    Time frame: Week 12

    We will track adverse events the participants experience

Secondary outcomes

  1. Pain - Visual Analog Scale

    Time frame: Week -2

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  2. Pain - Visual Analog Scale

    Time frame: Week 0 - Immediately before injection

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  3. Pain - Visual Analog Scale

    Time frame: Week 0 - Immediately after injection

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  4. Pain - Visual Analog Scale

    Time frame: Week 2

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  5. Pain - Visual Analog Scale

    Time frame: Week 6

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  6. Pain - Visual Analog Scale

    Time frame: Week 12

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

  7. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

  8. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

  9. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

  10. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

  11. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

  12. Pain - EQ-5D-5L

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  13. Pain - EQ-5D-5L

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  14. Pain - EQ-5D-5L

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  15. Pain - EQ-5D-5L

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  16. Pain - EQ-5D-5L

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  17. Disease Severity - Complex Regional Pain Syndrome Severity Score

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

  18. Disease Severity - Complex Regional Pain Syndrome Severity Score

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

  19. Disease Severity - Complex Regional Pain Syndrome Severity Score

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

  20. Disease Severity - Complex Regional Pain Syndrome Severity Score

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

  21. Disease Severity - Complex Regional Pain Syndrome Severity Score

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

  22. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

  23. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

  24. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

  25. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

  26. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

  27. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

  28. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

  29. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

  30. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

  31. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

  32. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

  33. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

  34. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

  35. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

  36. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

  37. Emotional and Psychological Function - EQ-5D-5L

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  38. Emotional and Psychological Function - EQ-5D-5L

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  39. Emotional and Psychological Function - EQ-5D-5L

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  40. Emotional and Psychological Function - EQ-5D-5L

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  41. Emotional and Psychological Function - EQ-5D-5L

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  42. Quality of Life - EQ-5D-5L

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  43. Quality of Life - EQ-5D-5L

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  44. Quality of Life - EQ-5D-5L

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  45. Quality of Life - EQ-5D-5L

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  46. Quality of Life - EQ-5D-5L

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

  47. Total Score - EQ-5D-5L

    Time frame: Week -2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

  48. Total Score - EQ-5D-5L

    Time frame: Week 0

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

  49. Total Score - EQ-5D-5L

    Time frame: Week 2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

  50. Total Score - EQ-5D-5L

    Time frame: Week 6

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

  51. Total Score - EQ-5D-5L

    Time frame: Week 12

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

Sponsors and collaborators

Lead sponsor

Ottawa Hospital Research Institute

Other

Registry information

Official study title

Peripheral Nerve Injections for the Treatment of Upper Extremity Complex Regional Pain Syndrome: a Feasibility Study for a Proposed Randomized Design

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Feb 9, 2021
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.